vs

Side-by-side financial comparison of Empire State Realty Trust, Inc. (ESRT) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $190.3M, roughly 1.7× Empire State Realty Trust, Inc.). Empire State Realty Trust, Inc. runs the higher net margin — 1.6% vs -18.2%, a 19.8% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 5.7%).

Empire State Realty Trust is a leading real estate investment trust that owns, manages, and operates a portfolio of premium commercial, residential, and retail properties primarily in the New York City metropolitan area, including the iconic Empire State Building. It serves corporate tenants, retail partners, and residential occupants, focusing on sustainable property operations and long-term asset value growth.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

ESRT vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.7× larger
MDGL
$321.1M
$190.3M
ESRT
Growing faster (revenue YoY)
MDGL
MDGL
+205.1% gap
MDGL
210.8%
5.7%
ESRT
Higher net margin
ESRT
ESRT
19.8% more per $
ESRT
1.6%
-18.2%
MDGL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ESRT
ESRT
MDGL
MDGL
Revenue
$190.3M
$321.1M
Net Profit
$3.0M
$-58.6M
Gross Margin
Operating Margin
15.5%
-18.6%
Net Margin
1.6%
-18.2%
Revenue YoY
5.7%
210.8%
Net Profit YoY
-73.7%
1.4%
EPS (diluted)
$0.20
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESRT
ESRT
MDGL
MDGL
Q1 26
$190.3M
Q4 25
$199.2M
$321.1M
Q3 25
$197.7M
$287.3M
Q2 25
$191.3M
$212.8M
Q1 25
$180.1M
$137.3M
Q4 24
$197.6M
$103.3M
Q3 24
$199.6M
$62.2M
Q2 24
$189.5M
Net Profit
ESRT
ESRT
MDGL
MDGL
Q1 26
$3.0M
Q4 25
$32.2M
$-58.6M
Q3 25
$13.6M
$-114.2M
Q2 25
$11.4M
$-42.3M
Q1 25
$15.8M
$-73.2M
Q4 24
$18.8M
$-59.4M
Q3 24
$22.8M
$-107.0M
Q2 24
$28.6M
Gross Margin
ESRT
ESRT
MDGL
MDGL
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Operating Margin
ESRT
ESRT
MDGL
MDGL
Q1 26
15.5%
Q4 25
17.8%
-18.6%
Q3 25
19.9%
-39.7%
Q2 25
18.4%
-22.2%
Q1 25
14.3%
-57.8%
Q4 24
21.7%
-64.8%
Q3 24
22.7%
-187.1%
Q2 24
20.8%
Net Margin
ESRT
ESRT
MDGL
MDGL
Q1 26
1.6%
Q4 25
16.1%
-18.2%
Q3 25
6.9%
-39.8%
Q2 25
6.0%
-19.9%
Q1 25
8.8%
-53.4%
Q4 24
9.5%
-57.5%
Q3 24
11.4%
-172.0%
Q2 24
15.1%
EPS (diluted)
ESRT
ESRT
MDGL
MDGL
Q1 26
$0.20
Q4 25
$0.11
$-2.55
Q3 25
$0.05
$-5.08
Q2 25
$0.04
$-1.90
Q1 25
$0.05
$-3.32
Q4 24
$0.07
$-2.50
Q3 24
$0.08
$-4.92
Q2 24
$0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESRT
ESRT
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$68.8M
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$1.8B
$602.7M
Total Assets
$4.4B
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESRT
ESRT
MDGL
MDGL
Q1 26
$68.8M
Q4 25
$132.7M
$198.7M
Q3 25
$154.1M
$295.7M
Q2 25
$94.6M
$186.2M
Q1 25
$187.8M
$183.6M
Q4 24
$385.5M
$100.0M
Q3 24
$421.9M
$232.7M
Q2 24
$535.5M
Total Debt
ESRT
ESRT
MDGL
MDGL
Q1 26
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Stockholders' Equity
ESRT
ESRT
MDGL
MDGL
Q1 26
$1.8B
Q4 25
$1.1B
$602.7M
Q3 25
$1.0B
$625.7M
Q2 25
$1.0B
$696.0M
Q1 25
$1.0B
$710.6M
Q4 24
$1.0B
$754.4M
Q3 24
$1.0B
$777.2M
Q2 24
$1.0B
Total Assets
ESRT
ESRT
MDGL
MDGL
Q1 26
$4.4B
Q4 25
$4.5B
$1.3B
Q3 25
$4.1B
$1.4B
Q2 25
$4.1B
$1.0B
Q1 25
$4.1B
$996.6M
Q4 24
$4.5B
$1.0B
Q3 24
$4.4B
$1.1B
Q2 24
$4.4B
Debt / Equity
ESRT
ESRT
MDGL
MDGL
Q1 26
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESRT
ESRT
MDGL
MDGL
Operating Cash FlowLast quarter
$-133.5M
Free Cash FlowOCF − Capex
$-133.8M
FCF MarginFCF / Revenue
-41.7%
Capex IntensityCapex / Revenue
10.0%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESRT
ESRT
MDGL
MDGL
Q1 26
Q4 25
$249.1M
$-133.5M
Q3 25
$105.3M
$79.8M
Q2 25
$26.7M
$-47.1M
Q1 25
$83.1M
$-88.9M
Q4 24
$260.9M
$-104.5M
Q3 24
$102.8M
$-67.0M
Q2 24
$37.1M
Free Cash Flow
ESRT
ESRT
MDGL
MDGL
Q1 26
Q4 25
$50.6M
$-133.8M
Q3 25
$72.8M
$79.0M
Q2 25
$-55.1M
Q1 25
$41.1M
Q4 24
$88.0M
$-104.7M
Q3 24
$-65.1M
$-67.8M
Q2 24
$19.5M
FCF Margin
ESRT
ESRT
MDGL
MDGL
Q1 26
Q4 25
25.4%
-41.7%
Q3 25
36.8%
27.5%
Q2 25
-28.8%
Q1 25
22.8%
Q4 24
44.5%
-101.3%
Q3 24
-32.6%
-109.0%
Q2 24
10.3%
Capex Intensity
ESRT
ESRT
MDGL
MDGL
Q1 26
10.0%
Q4 25
99.6%
0.1%
Q3 25
16.5%
0.3%
Q2 25
42.8%
0.0%
Q1 25
23.4%
0.0%
Q4 24
87.5%
0.2%
Q3 24
84.1%
1.3%
Q2 24
9.3%
Cash Conversion
ESRT
ESRT
MDGL
MDGL
Q1 26
Q4 25
7.74×
Q3 25
7.72×
Q2 25
2.35×
Q1 25
5.27×
Q4 24
13.88×
Q3 24
4.51×
Q2 24
1.30×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESRT
ESRT

Rental revenue (1)$166.1M87%
Observatory revenue$18.5M10%
Other revenue and fees$4.1M2%
Lease termination fees$1.4M1%
Third-party management and other fees$277.0K0%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons